• Lantern Pharma highlighted its AI platform RADR, citing 88% accuracy for patient stratification to support targeted oncology trials.
• Management framed RADR as a lever to cut early-stage development timelines by 70% and costs by 80%.
• LP-300 NSCLC program remains in Phase 2; interim data cited an 86% clinical benefit rate and 87% disease control rate as of May 11, 2026.
• Trial focus shifted to EGFR exon 21 L858R; median PFS cited at 8.4 months with target lesion decreases in over 70% of evaluable patients.
• LP-184 completed Phase 1a enrollment; LP-284 is in Phase 1; PredictBBB cited 94% benchmark accuracy for blood-brain barrier permeability prediction.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lantern Pharma Inc. published the original content used to generate this news brief on July 01, 2026, and is solely responsible for the information contained therein.